Table 4 Plasma pharmacokinetics of SP1049C doxorubicin

Patient number	Dose (mg m⁻²)	Dose (mg)	AUC (h μg ml⁻¹)	Vc (l)	Cl (l h⁻¹)	T_1/2 α (h)	T_1/2 β (h)	T_1/2 γ (h)
1	5	10.2	0.10	1.27	0.60	0.110	2.02	25.20
2	10	17.0	0.16	1.81	0.46	0.073	1.76	NA
3	20	33.0	0.38	12.20	84.2	0.083	0.25	31.10
4	35	50.0	2.19	22.70	34.4	0.114	1.96	65.50
6	35	53.0	2.02	26.40	30.2	0.160	3.15	68.00
7	35	55.0	1.44	36.90	40.8	0.157	4.76	59.10
8	35	77.0	1.13	56.90	81.4	0.162	9.55	97.00
9	35	66.0	2.15	35.20	33.1	0.142	6.82	98.70
10	35	60.0	1.37	8.48	41.7	0.071	0.83	25.90
11	50	108.0	2.19	12.70	44.5	0.073	0.69	27.10
12	50	84.0	1.58	55.60	48.6	0.129	1.89	64.10
13	50	121.5	1.65	15.10	63.3	0.069	3.88	47.60
14	50	85.0	2.16	8.51	34.9	0.065	0.89	25.40
15	50	95.0	1.54	50.40	78.7	0.176	6.05	102.00
16	50	95.0	1.93	10.60	47.3	0.084	1.24	35.20
17	70	140.0	4.08	35.90	65.2	0.132	1.07	42.00
18	70	120.0	3.21	10.80	37.7	0.086	2.96	31.50
19	70	134.0	4.20	5.85	29.0	0.089	2.79	31.00
20	70	123.0	2.19	25.00	67.1	0.093	3.05	32.70
21	90	167.0	3.70	39.30	56.4	0.183	4.94	65.50
22	90	185.0	2.91	8.04	46.2	0.062	0.73	22.30
23	90	189.0	4.29	45.40	56.8	0.105	2.96	49.50
24	70	125.0	1.62	18.30	71.4	0.089	1.73	21.30
25	70	154.0	2.95	49.40	87.4	0.108	2.83	39.20
26	70	120.0	2.09	24.10	56.8	0.082	1.91	56.50

Quick links

Search